Study of B013 and Nab-Paclitaxel for Locally Advanced or Metastatic Triple Negative Breast Cancer

Inclusion Criteria:

1. Women or men aged 18 -75 years

2. Locally advanced or metastatic triple negative breast cancer (TNBC)

3. No prior chemotherapy or targeted systemic therapy for inoperable locally advancedor metastatic TNBC

4. ECOG performance status of 0 or 1

5. Patient must have measurable or evaluable disease as defined by RECIST v1.1.Measurable lesions will be confirmed by radiographic imaging (CT or MRI)

Exclusion Criteria:

1. Previous treatment is eligible.

2. Spinal cord compression not definitively treated with surgery and/or radiation priorto study entry

3. Known central nervous system (CNS) disease

4. Uncontrolled pleural effusion, pericardial effusion, or ascites Patients

5. Uncontrolled tumor-related pain prior to study entry

6. The patient has a history of another malignancy within 5 years prior to study entry,except adequately treated non-melanotic skin cancer, carcinoma in situ of the cervixor Papillary carcinoma of the thyroid

7. Pregnancy or lactation